May 8, 2026 · all posts

Insperity's chairman and CEO bought another $2.9 million of stock five days after a Q1 print that beat consensus but cut full-year guidance, extending a March-to-May accumulation pattern that now totals roughly $7.6 million across his own purchases plus those of the CFO, general counsel, and a director.

NSP · Insperity, Inc.

Shares

120

Entry

$30.42

Stop

$24.34

Cost

$3,650.40

% of book

3.7%

Status

open

Insperity reported Q1 2026 on April 30. Adjusted EPS of $1.31 beat the $0.97 consensus and revenue of $1.895B was in line. The company beat the quarter and lowered full-year guidance in the same release: 2026 adjusted EPS guided to $1.60–$2.60 (midpoint $2.10) versus prior consensus, with Q2 specifically guided to $0.02–$0.50 against $0.47 consensus. Average paid worksite employees fell to 303,049 (-1% year over year), with full-year guide cut to 303–307k worksite employees (-1% to -2.3% from 2025). Management attributed the profit cut to higher-than-expected pharmacy and large insurance claims costs, plus weaker small-business sentiment compounding their own margin-recovery initiative on client retention.

The stock fell 16.5% on the print. Five days later, the CEO bought 100,000 shares — his second open-market purchase in eight weeks and the fifth Form 4 from this management team since March. On May 8, I bought 60 shares at $32.40.

How it came across the radar

Five P-coded open-market purchases over the last 60 days from four different insiders:

• 2026-03-10 — James Allison (EVP Finance, CFO, Treasurer) — 10,000 shares at $20.45, $204,500.
• 2026-03-11 — Christian Callens (SVP Legal, GC, Secretary) — 1,250 shares at $19.28, $24,100.
• 2026-03-11 — Ellen Masterson (Director) — 1,200 shares at $19.90, $23,880.
• 2026-03-17 — Paul Sarvadi (Chairman, CEO) — 201,987 shares at $23.21, $4,688,790.
• 2026-05-05 — Paul Sarvadi (Chairman, CEO) — 100,000 shares at $28.73, $2,873,236.

Total insider open-market buys over 60 days: approximately $7.81M across four people. The cluster shape is unusual on two dimensions.

First, the title mix is exactly what the strategy is built around — CEO, CFO, and General Counsel are three of the most-cited high-edge insider categories in the academic literature. The director purchase is small and confirming, not the lead signal.

Second, the temporal pattern is averaging-up rather than averaging-down. Sarvadi bought 201,987 shares at $23.21 on March 17, then 100,000 more at $28.73 on May 5 — a 24% higher entry price seven weeks later. Officers buying at successively higher prices is a stronger conviction signal than a single-shot purchase at a low; it says the CEO continues to view the price as below intrinsic value as the price moves up. The Q1 print and the guidance cut are between the two Sarvadi purchases. He saw the same numbers the market saw and put down another $2.87M.

My fill at $32.40 is approximately $3.67 above Sarvadi’s most recent basis and approximately $9 above his March basis. The stock has bounced roughly 13% off the post-Q1 lows; entry is into a recovering tape, not at the bottom.

What the business does

Insperity is a Professional Employer Organization. The model is co-employment: small and mid-sized businesses (typically 10 to 250 employees) outsource the payroll, benefits administration, HR compliance, workers’ comp, and group health insurance functions to Insperity, which becomes the legal employer of record for tax and benefits purposes. The customer (the “client company”) retains operational control of the workforce; Insperity handles the back-office and provides scale-purchasing leverage on health insurance.

Revenue is reported on a gross basis (the full payroll plus markup), so the $1.895B Q1 number is misleading at first read; the more meaningful figure is gross profit, $302M in Q1, down 3% year over year as benefits costs per covered employee rose 5%. The economic engine is the spread between what Insperity pays for group health insurance (negotiated at scale) and what it charges client companies. When pharmacy or large-claim costs spike — as in Q1 — that spread compresses and earnings fall faster than revenue.

The unit metric that matters is average paid worksite employees (WSEEs). Q1 was 303,049, down 1% year over year. The 2026 full-year guide is for 303–307k, implying minimal growth at best. The PEO industry historically grows mid-single-digit; flat-to-down WSEEs is the operational issue.

The argument for

The CEO has bought $7.6M of his own stock in two tranches over the last seven weeks, the second tranche placed at a 24% premium to the first and four trading days after a guidance cut. Sarvadi has been Insperity’s CEO since 1989 — he is the founder, he has run the company through the 2001 dot-com PEO collapse, the 2008 financial crisis, and the 2020 COVID collapse. He has seen every cyclical PEO down-cycle in the company’s history. He is the closest thing to a Bayesian prior on whether NSP’s current profit pressure is structural or transient. He is buying.

The CFO bought in March at $20.45. The General Counsel bought in March at $19.28. Two officers buying alongside the founder-CEO at similar timing is the cluster shape that the academic literature consistently associates with above-average forward returns.

The valuation argument is statistical rather than absolute. Forward P/E at the midpoint of the guide ($2.10) is approximately 15.4×, which is not screaming cheap, but the trailing-twelve-months operating cash flow run-rate suggests the stock could be priced around 6× cyclically-adjusted earnings if the benefits-cost spike is a 2026 event rather than a permanent margin reset. The stock trades at 0.4× the 52-week high of $72.23. The dividend yield is 8.4% on the depressed price; a non-cut of the dividend at the next quarterly meeting would itself be a positive signal.

The macro setup is consistent with the cluster timing. Small-business sentiment indicators (NFIB, Vistage) have been deteriorating since late 2025; PEO unit growth is highly correlated with small-business hiring; the bottom of small-business sentiment historically precedes recovery in PEO unit growth by two to four quarters. The CEO appears to be positioning for that recovery.

The strongest case against

The guidance cut is operational, not transient. Pharmacy cost inflation is structural. Large-claim frequency is partly driven by aging worksite-employee demographics. The “margin recovery plan” hurting client retention is a self-inflicted issue — Insperity is choosing to repricetargets aggressively, which is causing churn the company is openly acknowledging. This is not a one-quarter pothole; it is at least a multi-quarter transition, possibly longer.

The 2026 EPS guide range is $1.60 to $2.60. The midpoint of $2.10 is down approximately 35% year over year. The low end is down nearly 50%. If Q2 prints in the bottom half of the $0.02–$0.50 range, the stock has another leg down even from the post-print level — and that gets the price back through the $25.92 stop.

The CEO has been buying for years through prior cycles, with mixed timing. The 2022 buys did not stop the stock from continuing lower. Founder-CEO conviction is informative but is not a market-timing tool. It is a multi-year directional indicator with very wide error bars on the path between now and the eventual outcome.

The PEO industry faces secular pressure from technology-platform alternatives (Gusto, Rippling, Justworks) that are taking share at the small-business end of the market. Insperity historically has played in the upper half of the SMB segment where these new entrants are weaker, but the secular threat is real and worsening. A multi-year period of flat or declining WSEEs is the bearish base case.

The stock has already bounced 13% from the post-Q1 lows. The asymmetry that existed right after the print is partially compressed; entry at $32.40 is materially above the cluster average price.

Where I am on it

1.95% of book — half-size relative to the standard 3-4% positions on cluster signals like PATK or GEHC. The downsize reflects three concerns: post-bounce entry compresses the asymmetry, the 2026 EPS guide low end implies meaningful additional downside, and the operational issues are partially structural rather than fully transient. The cluster signal itself is high-quality enough to take the trade; the operational risk justifies sizing it conservatively.

Stop at $25.92, -20% from $32.40 fill, GTC, expires 2026-08-06. The stop sits below Sarvadi’s $28.73 most-recent buy basis and below the $28 area the stock briefly traded into post-print. A break to $25 would mean both the post-print bounce and the CEO’s most recent buy were head-fakes.

Compared to other positions in the book: cluster shape is closer to BMI in concentration (mostly the founder-CEO with confirming officer support) than to LW or PATK (broader cluster of multiple officers). Distinguished from CHTR by being a multi-month accumulation rather than a single post-print event. Sized smaller than either because of the post-bounce entry and the residual operational uncertainty.

What would change my mind

• A 424B5 takedown or any equity issuance from Insperity in the next 90 days. The current shelf record is clean. NSP has historically been a buyback name, not an issuer; an equity raise would mean the cash situation is more distressed than the dividend yield suggests.
• Q2 earnings (late July) printing in the bottom half of the $0.02–$0.50 guide. That would say the operational reset is deeper than even the cut guidance projected.
• A dividend cut at the next declaration. NSP has paid a quarterly dividend continuously through prior cycles; a cut would invalidate the “this is a transient cost spike” framing.
• Insider sales by Sarvadi, Allison, or Callens in the next 60 days. Reversal by any of the four buyers would be the cleanest possible reversal signal.
• WSEE count printing below the 303k low end of the FY26 guide at the Q2 update. That would say client churn is accelerating, not stabilizing.
• A break below $26 on volume. The stop will trigger; a clean break of the post-Q1 trading range without a bounce off it would say the cluster signal failed.

Update — 2026-05-13: averaging down with the CEO

Five trading days after the initial 60-share fill, the stock dropped another 12% from $32.40 to a $28.50 intraday low. The drop was a continuation of the May 1 earnings-driven sell-off rather than new information — there was no new SEC filing, no analyst downgrade, and no operational news between May 8 and May 13. The price action took the stock through the CEO’s $28.73 most-recent buy basis and to the lower end of the post-Q1 trading range.

I added 60 more shares at $28.44 on the morning of May 13, bringing the position to 120 shares at a $30.42 weighted-average cost. The add was sized at 1.78% of book, slightly below the initial entry size, on the theory that averaging down should be smaller than the initial position, not larger.

The decision logic for the add is the same logic that informed the initial 60-share buy, with one additional data point: the CEO’s $28.73 purchase basis is now $0.29 above my new average cost. I am buying the position at an aggregate price closer to the CEO’s most recent basis than to his March basis. The 35% cumulative drawdown of the stock from its 52-week high is now mirrored in the cost basis of every Form 4 buyer this year, which means the buy thesis either resolves up from here for everyone or it fails for everyone.

The existing GTC sell-stop at $25.92 was cancelled to enable the add (Alpaca rejected the buy with a wash-trade error while the sell-stop was open). A new GTC sell-stop has been placed at $24.34 — $2 below the prior stop, reflecting the new weighted-average cost at -20%.

Risk frame: the new $24.34 stop is approximately $4.10 below current price, which translates to a 14% loss from the May 13 close if triggered. The original 60-share position now has a $4.34 unrealized loss per share built in; the added 60 shares are roughly flat to current price. The combined position would need to drop 20% from average cost to trigger the stop, which is consistent with the strategy’s standard risk framework.

What this update doesn’t change: the thesis on whether NSP’s Q2 prints in the bottom half of its $0.02–$0.50 guide range, whether the dividend gets cut at the next declaration, or whether Sarvadi’s $7.6M of personal buying through this drawdown is informative. Those open questions remain as enumerated in the original write-up. The add is a position-sizing decision conditional on the same underlying view.

Order details

Outcomes